frenzy, page-37

re: sirtex goal: $5 then $8 -$9 The market cap of around $170 million is still remarkably cheap for a company that has a proven and increasingly utilised treatment for liver cancer.

If this stock went to $10 the market cap would still only be fractionally over $500 million, given the forecast growth in earnings a shareprice of $10 within the next 12 months may not be beyond the realms of possibility, especially if there becomes a takeover battle.